{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:02:28Z","timestamp":1788346948243,"version":"build-2803163510"},"reference-count":103,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81560381"],"award-info":[{"award-number":["81560381"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e27077","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T02:37:59Z","timestamp":1708742279000},"page":"e27077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Thyroid dysfunction (TD) induced by PD-1\/PD-L1 inhibitors in advanced lung cancer"],"prefix":"10.1016","volume":"10","author":[{"given":"Yanling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2226-5387","authenticated-orcid":false,"given":"Ping","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.heliyon.2024.e27077_bib1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-17-0063","article-title":"Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center","volume":"6","author":"Lisberg","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e27077_bib2","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1080\/0284186X.2021.1958006","article-title":"Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database","volume":"60","author":"Percik","year":"2021","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27077_bib3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1089\/thy.2019.0726","article-title":"Overt thyroid dysfunction and anti-thyroid antibodies predict response to anti-PD-1 immunotherapy in cancer patients","volume":"30","author":"Basak","year":"2020","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27077_bib4","article-title":"Thyroid dysfunction in lung cancer patients treated with immune checkpoint inhibitors (ICIs): outcomes in a Multiethnic urban cohort","volume":"13","author":"D'Aiello","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27077_bib5","first-page":"1446","article-title":"New progress in research on global cancer incidenc","volume":"16","author":"Tian","year":"2021","journal-title":"China Medicine"},{"issue":"Suppl 1","key":"10.1016\/j.heliyon.2024.e27077_bib6","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1634\/theoncologist.2019-IO-S1-s02","article-title":"Retrospect and prospect for lung cancer in China: clinical advances of immune checkpoint inhibitors","volume":"24","author":"Lu","year":"2019","journal-title":"Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27077_bib7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12272-021-01312-y","article-title":"Mechanisms of resistance to chemotherapy in non-small cell lung cancer","volume":"44","author":"Min","year":"2021","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27077_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.19.01154","article-title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer","volume":"38","author":"Noronha","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27077_bib9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib10","first-page":"14","article-title":"Gene expression and clinical characteristics of molecular targeted TTerapy in nonsmall cell lung cancer patients in shandong","volume":"20","author":"Qiao","year":"2017","journal-title":"Chin. J. Lung Cancer"},{"issue":"19","key":"10.1016\/j.heliyon.2024.e27077_bib11","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27077_bib12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e27077_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.627089","article-title":"Fatal adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Yu","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.heliyon.2024.e27077_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107296","article-title":"Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer","volume":"91","author":"Zhou","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27077_bib15","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00262-020-02802-6","article-title":"Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study","volume":"70","author":"Thuillier","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27077_bib16","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","author":"Yamauchi","year":"2017","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27077_bib17","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1089\/thy.2020.0075","article-title":"Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27077_bib18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.autrev.2018.02.001","article-title":"TCRalphabeta(+)CD3(+)CD4(-)CD8(-) (double negative) T cells in autoimmunity","volume":"17","author":"Brandt","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27077_bib19","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/clinchem\/hvaa081","article-title":"Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis","volume":"66","author":"von Itzstein","year":"2020","journal-title":"Clin. Chem."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27077_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102649","article-title":"Hashimoto's thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation","volume":"19","author":"Ralli","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e27077_bib21","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/cas.14363","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.heliyon.2024.e27077_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cyto.2019.01.003","article-title":"Immunological aspects of autoimmune thyroid disease - complex interplay between cells and cytokines","volume":"116","author":"Luty","year":"2019","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27077_bib23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4049\/jimmunol.141.3.849","article-title":"Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones","volume":"141","author":"Paliard","year":"1988","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27077_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1163462","article-title":"Role of IL-2 in cancer immunotherapy","volume":"5","author":"Jiang","year":"2016","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib25","first-page":"32","article-title":"Anticancer drug-induced thyroid dysfunction","volume":"16","author":"Bhattacharya","year":"2020","journal-title":"Eur. Endocrinol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27077_bib26","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27077_bib27","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0458","article-title":"Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation","volume":"4","author":"Bald","year":"2014","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27077_bib28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nm.4466","article-title":"High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy","volume":"24","author":"Krieg","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27077_bib29","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.21873\/anticanres.15110","article-title":"Cytokine-based cancer immunotherapy: challenges and opportunities for IL-10","volume":"41","author":"Rallis","year":"2021","journal-title":"Anticancer Res."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27077_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102590","article-title":"Immune checkpoint inhibitors-induced autoimmunity: the impact of gender","volume":"19","author":"Triggianese","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.heliyon.2024.e27077_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management","volume":"12","author":"Zhan","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27077_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27077_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int. Immunol."},{"issue":"6080","key":"10.1016\/j.heliyon.2024.e27077_bib34","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.1217718","article-title":"The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut","volume":"336","author":"Kawamoto","year":"2012","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27077_bib35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): national health and nutrition examination survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27077_bib36","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1210\/jcem-46-6-859","article-title":"Association of serum antithyroid antibodies with lymphocytic infiltration of the thyroid gland: studies of seventy autopsied cases","volume":"46","author":"Yoshida","year":"1978","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib37","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/er.2013-1055","article-title":"Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity","volume":"35","author":"McLachlan","year":"2014","journal-title":"Endocr. Rev."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27077_bib38","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s40618-019-01058-x","article-title":"Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors","volume":"42","author":"Mazarico","year":"2019","journal-title":"J. Endocrinol. Invest."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27077_bib39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27077_bib40","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.heliyon.2024.e27077_bib41","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fimmu.2019.01147","article-title":"The CD14(+)HLA-DR(lo\/neg) monocyte: an immunosuppressive phenotype that restrains responses to cancer immunotherapy","volume":"10","author":"Mengos","year":"2019","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27077_bib42","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1172\/JCI45862","article-title":"Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice","volume":"121","author":"Lu","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"18","key":"10.1016\/j.heliyon.2024.e27077_bib43","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1158\/1078-0432.CCR-15-0260","article-title":"Intratumoral CD14+ cells and circulating cd14+hla-DRlo\/neg monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma","volume":"21","author":"Gustafson","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib44","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1252013","article-title":"Immunosuppressive CD14(+)HLA-DR(lo\/neg) monocytes are elevated in pancreatic cancer and \"primed\" by tumor-derived exosomes","volume":"6","author":"Javeed","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.heliyon.2024.e27077_bib45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-015-0082-0","article-title":"Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo\/neg)) found in aggressive pediatric sarcoma patients","volume":"3","author":"Hingorani","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27077_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13343","article-title":"Circulating CD14(+) HLA-DR(lo\/-) monocytic cells as a biomarker for epithelial ovarian cancer progression","volume":"85","author":"Stenzel","year":"2021","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.heliyon.2024.e27077_bib47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fimmu.2014.00147","article-title":"Cancer vaccines in the world of immune suppressive monocytes (CD14(+)HLA-DR(lo\/neg) cells): the gateway to improved responses","volume":"5","author":"Laborde","year":"2014","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27077_bib48","doi-asserted-by":"crossref","first-page":"924","DOI":"10.2174\/1871530319666191125150929","article-title":"Variation in the level of thyroid markers in association with inflammation in patients with type 2 diabetes","volume":"20","author":"Siddiqui","year":"2020","journal-title":"Endocr., Metab. Immune Disord: Drug Targets"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27077_bib49","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1507\/endocrj.EJ13-0030","article-title":"The influence of body mass index and low-grade systemic inflammation on thyroid hormone abnormalities in patients with type 2 diabetes","volume":"60","author":"Moura Neto","year":"2013","journal-title":"Endocr. J."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27077_bib50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jdermsci.2017.07.007","article-title":"Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab","volume":"88","author":"Fujisawa","year":"2017","journal-title":"J. Dermatol. Sci."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27077_bib51","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27077_bib52","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.7150\/jca.53242","article-title":"Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study","volume":"12","author":"Egami","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e27077_bib53","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/CMAR.S293200","article-title":"Peripheral blood markers associated with immune-related adverse effects in patients who had advanced non-small cell lung cancer treated with PD-1 inhibitors","volume":"13","author":"Liu","year":"2021","journal-title":"Cancer Manag. Res."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27077_bib54","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00262-020-02585-w","article-title":"Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors","volume":"69","author":"Peng","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27077_bib55","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa458","article-title":"Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index","volume":"105","author":"Pollack","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12902-022-01004-8","article-title":"Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients","volume":"22","author":"Baek","year":"2022","journal-title":"BMC Endocr. Disord."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27077_bib57","doi-asserted-by":"crossref","first-page":"T47","DOI":"10.1530\/JOE-13-0339","article-title":"Adipocytokines in obesity and metabolic disease","volume":"220","author":"Cao","year":"2014","journal-title":"J. Endocrinol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27077_bib58","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1210\/jc.2009-2798","article-title":"Investigations of thyroid hormones and antibodies in obesity: leptin levels are associated with thyroid autoimmunity independent of bioanthropometric, hormonal, and weight-related determinants","volume":"95","author":"Marzullo","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27077_bib59","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4158\/EP-2018-0472","article-title":"Baseline tsh level is associated with risk of anti-Pd-1-Induced thyroid dysfunction","volume":"25","author":"Pollack","year":"2019","journal-title":"Endocr. Pract."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e27077_bib60","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin. Endocrinol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib61","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12020-021-02750-w","article-title":"Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy","volume":"74","author":"Rubino","year":"2021","journal-title":"Endocrine"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e27077_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215465","article-title":"Factors associated with thyroid-related adverse events in patients receiving PD-1 or PD-L1 inhibitors using machine learning models","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27077_bib63","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1097\/JTO.0000000000000687","article-title":"Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer","volume":"10","author":"Calles","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27077_bib64","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib65","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12967-021-02784-8","article-title":"The role of opioids in cancer response to immunotherapy","volume":"19","author":"Botticelli","year":"2021","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib66","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101370","article-title":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","volume":"34","author":"Elia","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27077_bib68","first-page":"930","article-title":"Study on the occurrence and related factors of thyroid dysfunction caused by PD-1 monoclonal antibody","volume":"25","author":"Wei","year":"2020","journal-title":"Chin. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e27077_bib69","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27077_bib70","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3803\/EnM.2020.906","article-title":"Characteristics of immune-related thyroid adverse events in patients treated with PD-1\/PD-L1 inhibitors","volume":"36","author":"Yoon","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27077_bib71","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/fcp.12453","article-title":"Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database","volume":"33","author":"Castinetti","year":"2019","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","article-title":"Next generation of immune checkpoint therapy in cancer: new developments and challenges","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27077_bib73","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J. Cancer"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e27077_bib74","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.4049\/jimmunol.1502643","article-title":"Genetic and epigenetic regulation of PD-1 expression","volume":"196","author":"Bally","year":"2016","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e27077_bib75","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27077_bib76","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.heliyon.2024.e27077_bib77","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2024.e27077_bib78","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fonc.2018.00386","article-title":"Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion","volume":"8","author":"Dong","year":"2018","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e27077_bib79","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1016\/j.celrep.2019.11.113","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"29","author":"Garcia-Diaz","year":"2019","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27077_bib80","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27077_bib81","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27077_bib82","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2024.e27077_bib83","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212289","article-title":"Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies","volume":"4","author":"Scarpace","year":"2015","journal-title":"Drugs Context"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib84","first-page":"49","article-title":"Research progress on the mechanism and clinical data of cereblon in reversing the resistance of lung cancer to PD-1 antibody by T cells","volume":"24","author":"Guo","year":"2021","journal-title":"Chin. J. Lung Cancer"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e27077_bib85","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/cam4.2806","article-title":"First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 \u226550% in a multicenter real-life cohort: the PEMBREIZH study","volume":"9","author":"Amrane","year":"2020","journal-title":"Cancer Med."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27077_bib86","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27077_bib87","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10030","key":"10.1016\/j.heliyon.2024.e27077_bib88","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27077_bib89","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1111\/1759-7714.13541","article-title":"Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients","volume":"11","author":"Song","year":"2020","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib90","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e27077_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/life11111277","article-title":"Treatment-related adverse events with PD-1 or PD-L1 inhibitors: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2021","journal-title":"Life"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27077_bib92","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e27077_bib93","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib94","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e27077_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100787","article-title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies","volume":"8","author":"Amoroso","year":"2023","journal-title":"Esmo Open"},{"key":"10.1016\/j.heliyon.2024.e27077_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e27077_bib97","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s00262-020-02803-5","article-title":"Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors","volume":"70","author":"Zhong","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib98","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","article-title":"Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab","volume":"19","author":"Masuda","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.heliyon.2024.e27077_bib99","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.lungcan.2018.11.007","article-title":"Corrigendum to \"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab\"","volume":"126","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27077_bib100","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.heliyon.2024.e27077_bib101","article-title":"Immune-related adverse events predict the efficacy of immune checkpoint inhibitors in lung cancer patients: a meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e27077_bib102","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2017","journal-title":"OncoImmunology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e27077_bib103","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3892\/ol.2022.13429","article-title":"Thyroid dysfunction during PD-1 inhibitor treatment in patients with cancer: incidence and association with progression-free survival","volume":"24","author":"Wu","year":"2022","journal-title":"Oncol. Lett."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024031086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024031086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:25:06Z","timestamp":1769045106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024031086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":103,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024031086"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27077","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid dysfunction (TD) induced by PD-1\/PD-L1 inhibitors in advanced lung cancer","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e27077"}}